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Background: Surfactant proteins SP-A and SP-D are useful biomarkers in diagnosis, monitoring, and prognosis of
idiopathic pulmonary fibrosis (IPF). Despite their high structural homology, their serum concentrations often vary in IPF
patients. This retrospective study aimed to investigate distinct compartmentalization of SP-A and SP-D in the vasculature
and lungs by bronchoalveolar lavage fluid (BALF)/serum analysis, hydrophilicity and immunohistochemistry.
Methods: We included 36 IPF patients, 18 sarcoidosis (SAR) patients and 20 healthy subjects. Low-speed centrifugal
supernatants of BALF (Sup-1) were obtained from each subject. Sera were also collected from each patient. Furthermore,
we separated Sup-1 of IPF patients into hydrophilic supernatant (Sup-2) and hydrophobic precipitate (Ppt) by
high-speed centrifugation. We measured SP-A and SP-D levels of each sample with the sandwich ELISA technique. We
analyzed the change of the BALF/serum level ratios of the two proteins in IPF patients and their hydrophilicity in BALF.
The distribution in the IPF lungs was also examined by immunohistochemical staining.
Results: In BALF, SP-A levels were comparable between the groups; however, SP-D levels were significantly lower in
IPF patients than in others. Although IPF reduced the BALF/serum level ratios of the two proteins, the change in
concentration of SP-D was more evident than SP-A. This suggests a higher disease impact for SP-D. Regarding
hydrophilicity, although more than half of the SP-D remained in hydrophilic fractions (Sup-2), almost all of the
SP-A sedimented in the Ppt with phospholipids. Hydrophilicity suggests that SP-D migrates into the blood more easily
than SP-A in IPF lungs. Immunohistochemistry revealed that SP-A was confined to thick mucus-filling alveolar space,
whereas SP-D was often intravascular. This data also suggests that SP-D easily leaks into the bloodstream, whereas SP-A
remains bound to surfactant lipids in the alveolar space.
Conclusions: The current study investigated distinct compartmentalization of SP-A and SP-D in the vasculature and
lungs. Our results suggest that serum levels of SP-D could reflect pathological changes of the IPF lungs more incisively
than those of SP-A.
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The pulmonary surfactant consists of phospholipids,
mainly dipalmitoyl phosphatidylcholine (DPPC), surfac-
tant protein (SP)-A, SP-B, SP-C, and SP-D. Both SP-A
and SP-D are produced by type II alveolar epithelial cells
and Clara cells, and are secreted into the alveolar space
[1,2]. Unlike SP-B and SP-C, they are hydrophilic pro-
teins belonging to the C-type lectin superfamily. Both
SP-A and SP-D play crucial roles in lung innate immun-
ity [3,4]. Moreover, their serum levels reflect the severity
and prognosis of interstitial lung diseases, including idio-
pathic pulmonary fibrosis (IPF) [5,6]. Although SP-A
and SP-D are very similar in terms of structures and
functions [7,8], they have different binding specificities
for phospholipids or glycolipids. Whereas SP-A specific-
ally binds to DPPC and galactosylceramide, SP-D binds
to phosphatidylinositol and glucosylceramide [9-12].
Patients diagnosed with IPF have a poor prognosis
(median survival approximately 3 years), with consider-
able individual variability in the clinical course [13,14].
Therefore, it is important to predict each patient’s prog-
nosis correctly for treatment optimization. Several prog-
nostic factors of IPF have been proposed, including age,
forced vital capacity (FVC), diffusing capacity (DLCO),
chronological changes in respiratory functions, and desat-
uration during the 6-min walk test [15-18]. On the other
hand, blood biomarkers of IPF are preferred because they
do not require an effort from the patients and are easy to
measure, namely SP-A, SP-D, Krebs von den Lungen-6
(KL-6), matrix metalloproteinase-7 (MMP-7), and chemo-
kine (C-C motif) ligand 18 (CCL18) [5,6,19-22]. In Japan,
SP-A, SP-D, and KL-6 are the most commonly used serum
biomarkers in diagnosis, monitoring, and prognosis of IPF,
with empirical data having accumulated for over 10 years.
Although SP-A and SP-D are proteins with high hom-
ology, we often experience IPF cases with differences in
serum levels for the two proteins [5]. In this study, we in-
vestigated dissociation between SP-A and SP-D in terms of
hydrophilicity, their levels in serum and bronchoalveolar
lavage fluid (BALF), and tissue distribution by immunohis-
tochemistry in healthy and IPF lungs.
Methods
Study subjects
This retrospective study included 54 consecutive patients
[36 IPF; 18 sarcoidosis (SAR)] who had a bronchoalveolar
lavage (BAL) performed at the Sapporo Medical Univer-
sity Hospital from December 2003 to May 2012. SAR
patients were used as disease controls because, in Japan,
they seldom show fibrotic changes in the lung, even with
pulmonary lesions [23,24]. The diagnosis of IPF was
based on pathological, clinical, and radiological findings,
according to the 2010 American Thoracic Society (ATS)/
European Respiratory Society (ERS)/Japanese RespiratorySociety (JRS)/Latin American Thoracic Association (ALAT)
statement [25]. A surgical lung biopsy was performed on
12 IPF patients. Sarcoidosis was diagnosed clinically
(N = 18) and histopathologically (N = 11) using the 2006
Japanese diagnostic standard and guidelines for sarcoidosis.
The Japanese guideline specifies the following diagnostic
criteria. 1) Histological demonstration of non-caseating epi-
thelioid cell granuloma in one organ in addition to one or
more of the following conditions: a) the same granuloma in
other organs; b) typical clinical findings in other organs
(chest radiographic findings, bronchoscopic findings, typical
ocular symptoms, cardiac symptoms and/or findings, typ-
ical skin eruption, and neuropathic and/or myopathic
symptoms); c) two or more of the following abnormalities
on examinations that reflect a systemic response of sarcoi-
dosis: bilateral hilar lymphadenopathy, elevated serum
angiotensin-converting enzyme levels, negative tuberculin
skin test, abnormal localizations on gallium scintigraphy, el-
evated lymphocytes and/or a high CD4/CD8 ratio in BALF,
and hypercalcemia and/or hypercalciuria. 2) In patients
with no histological evidence, the above-mentioned typical
clinical findings in two or more organs in addition to ab-
normal results in two or more of the above-mentioned six
examinations. 3) Exclusion of other diseases showing simi-
lar histological or clinical findings. One patient was diag-
nosed by surgical lung biopsy, seven by transbronchial lung
biopsy, and three by biopsy of other organs. Some patients
had granular shadows or nodules on their lung field, but no
fibrotic pattern. At the time of BAL fluid collection, none
of the patients received corticosteroids or immunosuppres-
sants and had any infection or any nutrition problems.
To compare BALF concentration of the two proteins,
this study also included a control group consisting of 20
healthy subjects from our previous study in which BAL
was conducted under the same conditions [26]. They had
no history of lung disease, and there was no abnormal
finding on physical examination, chest radiograph, and
pulmonary function tests. This research was conducted in
accordance with the Declaration of Helsinki (1964), and
has obtained the approval of the Ethics Committee of the
Sapporo Medical University.BAL technique
Each participant received an intramuscular injection of at-
ropine sulfate and hydroxyzine or pethidine, followed by
local anesthesia with lidocaine. A flexible bronchofiber-
scope (OLYMPUS, Tokyo, Japan) was inserted orally to
pour 50 mL of 0.9% saline (37°C) into the bronchus of the
right middle lobe or the left lingula, and the BALF was re-
covered. This process was repeated three times and the
fractions pooled together. BALF was centrifuged (5 min;
1,000 g) to remove cell components, and this Sup-1 was
cryopreserved at −80°C until use.
Nishikiori et al. BMC Pulmonary Medicine 2014, 14:196 Page 3 of 10
http://www.biomedcentral.com/1471-2466/14/196Measurements of SP-A and SP-D levels
The SP-A content of Sup-1 was measured using a sandwich
enzyme linked immunosorbent assay (ELISA), named SP-A
Test/Kokusai-F (Sysmex Co., Kobe, Japan), as previously
described [27]. A standard ELISA kit was used to measure
SP-D (Yamasa Co. Choshi, Japan), including recombinant
human SP-D as the standard, and two monoclonal anti-
bodies against human SP-D (6B2 and 7C6). In addition, per-
ipheral venous blood samples were obtained from each
patient within 1 week before BAL collection. Serum SP-A
and SP-D levels were determined using the same tech-
niques. We calculated BALF/serum level ratios of the two
proteins for each patient, and compared the ratios of two
diseases.
Hydrophilicity of SP-A and SP-D
The hydrophilicity of SP-A and SP-D in the BALF of IPF
patients (N = 19) were measured after centrifugation of
1.2 mL of Sup-1 (33,000 g; 4°C; 16 h) into a supernatant
(Sup-2) and precipitate (Ppt). The Ppt was resuspended
in 1.2 mL of 0.9% saline. The concentrations of SP-A
and SP-D in Sup-2 and Ppt were measured by ELISA as
stated above. Following which, the phospholipids were
extracted from Sup-2 and Ppt by the method of Bligh
and Dyer [28], and the total amount was measured by
the method of Bartlett [29].
Immunohistochemistry
Immunohistochemical analysis was performed on surgical
lung biopsies from 12 IPF patients, as well as peripheral
noncancerous control lung tissue from three patients with
primary lung cancer obtained by lobectomy. The tissue
samples were fixed in 10% buffered formalin (18 h) and em-
bedded in paraffin. Then, 3-μm thick sections were deparaf-
finized and stained using the following protocols. The
primary antibodies were mouse anti-human SP-A mono-
clonal antibodies (PE10, IBL, JAPAN), and mouse anti-
human SP-D monoclonal antibodies (12G5, Abcam, UK).
Thereafter, the sections were incubated with biotin-labeled
secondary antibody (VECTASTAIN ABC Mouse IgG Kit;
Vector Labs, USA), and stained using the DAB Peroxidase
Substrate Kit (Vector Labs, USA). For SP-D, samples were
pretreated in 10 mM citric acid solution (121°C; 15 min)
before being incubated with the primary antibody.
Furthermore, the stained sections were boiled in 10 mM
citric acid solution (121°C; 15 min) to remove antibodies,
and stained again with monoclonal CD34 (NU-4A1,
Nichirei, JAPAN) or monoclonal D2-40 (N1607, Dako,
USA) as primary antibodies. Double immunostaining was
performed using the Vectastain ABC-AP Mouse IgG Kit
(Vector Labs, USA) and the alkaline phosphatase sub-
strate kit (Vector Red; Vector Labs, USA). CD34 stains
vascular endothelium, particularly in small capillaries [30],
whereas D2-40 stains lymphatic endothelium [31].The semi-qualitative analysis of immunohistochemistry
was performed with concordance of three well-trained pul-
monologists who had knowledge of the pathologic features
of interstitial pulmonary diseases. We defined immunohis-
tochemical intensities of normal type II epithelial cells as
positive; “+”, and expressed those of each area using five
grades: “−”, none; “±”, more or less; “+”, positive; “++”, more
intense; and “+++”, very intense.
Statistical analysis
All analyses were performed using the SPSS Statistics 21
(IBM Inc.). The data of age and the BALF recovery rate
with symmetric distribution are expressed as mean ±
standard deviation, and the differences between the
three groups were tested using one-way ANOVA. The
differences between each pair of the three groups were
tested using Tukey’s HSD test. The data of SP-A and SP-
D levels in the serum and BALF, the BALF/serum level
ratios of the two proteins, and the percentages of surfac-
tant proteins and phospholipids fragmentation in Sup-2
or Ppt showed asymmetric distributions. These data are
expressed as median (interquartile range), and tested using
the Mann–Whitney U–test (between the two groups) or
the Kruskal Wallis test (among three groups). The differ-
ences between each pair of the three groups were tested
using the Mann–Whitney U–test with Bonferroni correc-
tion. The differences in sex and the smoking status were
tested using the chi-square test. The correlations between
the two variables were evaluated using the Spearman’s




The basic characteristics and recovery rates of BALF of
each subject group are summarized in Table 1. Most IPF
patients and healthy subjects were men, whereas both
genders were almost equally represented in the SAR
patients. The mean age of both the disease groups was
2-fold higher than that of the healthy group (P < 0.001).
The smoking status of disease groups was also different
from that of the healthy group. Moreover, the percent
recovery of BALF was significantly lower in both the
disease groups, compared with the healthy group.
SP-A and SP-D levels in BALF and serum
The data of SP-A and SP-D levels of each subject group
are summarized in Table 1. Serum concentration of SP-
A and SP-D in IPF patients [median 84.5 ng/mL (inter-
quartile range 55.5 – 115.8 ng/mL) and 272.0 ng/mL
(172.0 – 441.8 ng/mL), respectively] was mostly above the
normal upper limit of previous reports [6,19,32], and higher
than that of SAR patients [33.3 ng/mL (26.1 – 52.0 ng/mL);
Table 1 Patient characteristics and the data of serum and BALF levels of SP-A and SP-D
IPF SAR HS
N 36 18 20
Sex (male: female) 18:8 8:10 P = 0.073 17:3 P = 0.339 P = 0.004
Age (years old) 67.6 ± 8.0 53.7 ± 16.2 P < 0.001 28.2 ± 6.3 P < 0.001 P < 0.001
Smoking status (current: ex-: never smoker) 7: 20: 9 4: 8: 6 P = 0.528 8: 0: 12 P < 0.001 P < 0.001
BALF recovery (%) 51.7 ± 16.5 57.9 ± 12.5 P = 0.513 66.1 ± 22.4 P = 0.001 P = 0.002
Serum SP-A level (ng/ml) 84.5 (55.5 – 115.8) 33.3 (26.1 – 52.0) P < 0.001 -
Serum SP-D level (ng/ml) 272.0 (172.0 – 441.8) 75.0 (48.8 – 97.3) P < 0.001 -
BALF SP-A level (ng/ml) 1275.0 (581.0 – 2672.5) 1600.0 (972.0 – 3220.0) 1978.0 (1380.0 – 3749.0) P = 0.245
BALF SP-D level (ng/ml) 379.0 (223.8 – 570.8) 704.5 (389.3 – 967.5) P = 0.003 667.0 (391.0 – 1219.0) P = 0.003 P < 0.001
BALF/serum ratio of SP-A levels 19.1 (6.9 – 41.6) 51.2 (18.5 – 103.8) P = 0.01 -
BALF/serum ratio of SP-D levels 1.3 (0.7 – 2.4) 7.8 (4.7 – 20.1) P < 0.001 -
The data of age and the BALF recovery rate with symmetric distribution are presented as mean ± standard deviation. Sex and the smoking status were evaluated
by the chi-square test. The other data show asymmetric distribution, which is presented as a median (interquartile range). P values below each data value were
calculated using the Mann–Whitney U–test to compare with the IPF group. P values in the rightmost column were calculated using the Kruskal–Wallis test to
analyze the distribution of data among the three groups. SP-A, surfactant protein A; SP-D, surfactant protein D; BALF, bronchoalveolar lavage fluid; HS, healthy
subjects; IPF, idiopathic pulmonary fibrosis patients; SAR, sarcoidosis patients.
Nishikiori et al. BMC Pulmonary Medicine 2014, 14:196 Page 4 of 10
http://www.biomedcentral.com/1471-2466/14/196P < 0.001 and 75.0 ng/mL (48.8 – 97.3 ng/mL); P < 0.001,
respectively].
Measurements of SP-A in BALF revealed comparable
concentrations between the three groups (P = 0.245): IPF
patients (median 1275.0 ng/mL), healthy subjects (median
1978.0 ng/mL), and SAR patients (median 1600.0 ng/mL)
(Figure 1A). In contrast, SP-D concentrations in the IPF
group (median 379.0 ng/mL) were significantly lower than
those in the healthy (median 667.0 ng/mL, P = 0.003) and
SAR groups (median 704.5 ng/mL, P = 0.003) (Figure 1B).
Because demographic differences were found among
groups and some original data of healthy subjects had
been lost, using multivariate analysis, we confirmed low
BALF SP-D level in the IPF group compared with the SAR
group (P = 0.016; Table 2).
The gaps between BALF and serum level (BALF/serum
level ratio) of SP-A and SP-D were median 19.1 (SP-A)
and 1.3 (SP-D) in IPF patients, and median 51.2 (SP-A)
and 7.8 (SP-D) in SAR patients. These gaps were signifi-
cantly smaller in IPF patients than in SAR patients
(SP-A: P = 0.01 and SP-D: P < 0.001) (Figure 2A, B).
Spearman’s rank coefficient analysis between BALF and
serum concentrations was conducted for each surfactant
protein in each disease group. There was no significant
correlation for SP-A in the IPF group, but a moderate
positive correlation was observed for SP-D in IPF patients
(r = 0.377, P = 0.023) (Figures 3A, B). In the SAR group,
significant correlation was not observed in both protein
concentrations between BALF and sera (data not shown).
Comparing the hydrophilicity of SP-A and SP-D in BALF
The BALF supernatant fractions from IPF patients
centrifuged to remove cellular components (Sup-1) were
centrifuged again (33,000 g) to generate a hydrophobicprecipitate (Ppt) and hydrophilic supernatant (Sup-2).
Nearly all the SP-A sedimented in the Ppt (median 97.9%),
indicating high hydrophobicity. In contrast, SP-D parti-
tioned into the two phases, but significantly more in
Sup-2 (median 52.4%). Finally, nearly all surfactant phos-
pholipids were collected in the Ppt (median 100.0%).
Together, these data suggest that hydrophilicity of SP-A is
weakened by binding with phospholipids in BALF. The re-
sults of centrifugation of BALF are summarized in
Table 3.Immunohistochemistry
The tissue distribution of SP-A and SP-D was analyzed
by immunostaining of surgical lung biopsies from IPF
patients and peripheral noncancerous control lung tissue
from lung cancer patients. Type II alveolar epithelial cells,
which are known to produce pulmonary surfactant, were
positive for both surfactant proteins in normal peripheral
lungs (Figures 4A, B) and IPF lungs (Figures 4C, D). In
fibrotic lesions where alveoli were severely collapsed, the
alveolar space had been covered by regenerated ciliated
epithelial cells. These cells were negative for SP-A and
SP-D, similar to normal ciliated epithelial cells. The ectatic
alveolar space was often filled with thick mucus strongly
immunoreactive to SP-A, but weakly immunoreactive to
SP-D (Figures 4E, F). Whereas SP-D was often expressed
inside blood vessels in the thick stroma, SP-A was always
negative (Figure 4G, H). Double immunostaining for
CD34 indicated that the capillary vessels adjacent to type
II alveolar epithelial cells were extremely hyperplastic
(Figure 5A). On the other hand, the lymphatic vessels
stained by D2-40 were not located near the alveolar space,
but concentrated at the center of the stroma (Figure 5B).
Figure 1 Surfactant protein (SP)-A and SP-D levels in bronchoalveolar lavage fluid (BALF). (A) There was no significant difference in SP-A
levels between patients and healthy subjects (HS). (B) The SP-D levels were significantly lower in idiopathic pulmonary fibrosis (IPF) patients than
in healthy subjects (P = 0.003) and sarcoidosis patients (SAR; P = 0.003).
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distribution comparing SP-A and SP-D is presented in
Table 4.
Discussion
It has been reported that serum SP-A and SP-D concen-
trations are elevated in IPF and other interstitial lung
diseases, and that they can predict the progression of re-
spiratory failure and prognosis in IPF [5,6]. However,
there was considerable variability in serum SP-A/SP-D
level ratio between patients. As an example for this vari-
ability, we presented the difference of serum concentra-
tion of these proteins between IPF patients with ground
glass opacities (GGO) and patients with consolidation-
dominant opacities by computed tomography [5]. Al-
though serum SP-D was elevated in both groups, serum
SP-A concentration was high only in patients with
GGO. SP-A and SP-D are proteins with high homology
in structure and function; however, these observations
supported differences in transition efficiency from the
alveolar space to the bloodstream.Table 2 The differences of each variable between IPF and
SAR group
Univariate analysis Multivariate analysis
Sex P = 0.073 P = 0.056
Age P < 0.001 P = 0.007
Smoking status P = 0.528 P = 0.277
BALF SP-A level P = 0.405 P = 0.082
BALF SP-D level P = 0.001 P = 0.016
The SP-D level in BALF of IPF patients was significantly decreased compared to
SAR patients with univariate and multivariate analysis. IPF, idiopathic pulmonary
fibrosis; SAR, sarcoidosis; BALF, bronchoalveolar lavage fluid; SP-A, surfactant
protein A; SP-D, surfactant protein D.We previously reported BALF concentrations of SP-D
equivalent or lower in IPF patients than in healthy sub-
jects [33]. Likewise, the present study revealed SP-D
levels in BALF to be significantly lower in IPF patients
than in SAR patients or healthy subjects. Besides,
McCormack et al. and Gunther et al. reported signifi-
cantly lower SP-A concentrations in the BALF of IPF
patients than in healthy subjects [33,34]. In the
current study, the SP-A concentration in BALF had a
tendency to decrease among IPF patients compared
with healthy subjects, but the difference was not sig-
nificant. Although the studies on the two proteins of
BALF show the same directionality, we find different
amplitudes in their levels between IPF and normal
lungs. The reasons for these differences are unclear. One
potential explanation is the ATS/ERS(/JRS/ALAT) guide-
line for idiopathic pulmonary fibrosis was revised in 2000
[35] and 2010 [25] and the current disease group may dif-
fer from those in previous studies.
According to the current study, the BALF/serum level
ratio of SP-A was reduced from 51:1 in the sarcoidosis
group to 19:1 in the IPF group. In contrast, IPF caused a
6-fold decrease in BALF/serum level ratio for SP-D, with
7.8:1 in the sarcoidosis group compared with 1.3:1 in the
IPF group. These data suggest that IPF caused a prefer-
ential leakage of SP-D from the alveolar space into the
bloodstream. Moreover, in this study, the SP-D concen-
trations in sera were correlated with those in BALF, but
such a correlation was not found for SP-A. This result may
be due to the higher permeability of SP-D, implying that
not only BALF concentration but also serum concentration
can be easily altered according to the amount of secretion
of SP-D from productive cells. Mogulkoc et al. reported
that the clearance of inhaled technetium 99 m-labelled
Figure 2 Bronchoalveolar lavage fluid (BALF)/serum level ratio of (A) SP-A and (B) SP-D. Concerning both SP-A and SP-D, the ratio was
smaller in idiopathic pulmonary fibrosis (IPF) patients than in sarcoidosis (SAR) patients (P = 0.01 and P < 0.001, respectively).
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was exacerbated among IPF patients and suggested that the
migration of substances from the alveolar space into the
bloodstream was accelerated [36]. One of the reasons for
this high permeability may be the impairment of the base-
ment membrane in IPF lungs where alveoli were collapsed
and replaced with fibrotic interstitium [37,38]. This impair-
ment of the basement membrane seems to promote the
transition of SP-A and SP-D into the bloodstream.
The present study revealed dissociation between SP-A
and SP-D in IPF lungs, suggesting that different pro-
tein–lipid interactions may affect their leakage into the
bloodstream. Most of the SP-A found in the alveolarFigure 3 Surfactant protein levels in serum and bronchoalveolar lava
was no correlation between BALF and serum SP-A levels. (B) Significant po
(r = 0.377; P = 0.023).space is bound to DPPC, which is the main component
of pulmonary surfactant [9]. In contrast, SP-D remains
in a lipid-free state in the alveolar space [11,39], which
could facilitate leakage from airspace into bloodstream.
Accordingly, the hydrophilicity experiments conducted
with BALF from IPF patients showed that nearly all
SP-A was sedimented in the Ppt after high-speed centri-
fugation, consistent with SP-A-DPPC complexing. In
contrast, SP-D partitioned significantly in the hydropho-
bic (Ppt) and hydrophilic (Sup-2) fractions. Accordingly,
SP-D (but not SP-A) was often immunolocalized inside
blood vessels in the fibrotic parenchyma. In contrast,
SP-A (but not SP-D) remained confined to the thickge fluid (BALF) of idiopathic pulmonary fibrosis patients. (A) There
sitive correlation between BALF and serum SP-D levels was observed
Table 3 Fragmentation of SP-A and SP-D in the
bronchoalveolar lavage fluid of idiopathic pulmonary
fibrosis patients
Sup-2 Ppt
SP-A (%) 2.1 (0.9 – 4.4) 97.9 (95.6 – 99.1) P < 0.001
SP-D (%) 52.4 (48.4 – 79.3) 47.6 (20.7 – 51.6) P = 0.011
Total Phospholipid (%) 0.0 (0.0 – 8.3) 100.0 (91.7 – 100.0) P < 0.001
Bronchoalveolar lavage fluid was centrifuged (1,000 g) to remove cell components
(Sup-1), and Sup-1 was centrifuged again (33,000 g) into a supernatant (Sup-2) and
precipitate (Ppt). The percentage of fragmentation of SP-A, SP-D and phospholipids
in each segment was examined. The data are presented as median





Figure 4 Immunohistochemistry of control lung tissue and lung biopsies f
the cytoplasm of type II alveolar epithelial cells was positive for (A) SP-A (brown)
were hyperplastic, and strongly positive for (C) SP-A (brown) and (D) SP-D (brow
tracts was highly immunoreactive for (E) SP-A but not for (F) SP-D. (G-H) Inside b
Nishikiori et al. BMC Pulmonary Medicine 2014, 14:196 Page 7 of 10
http://www.biomedcentral.com/1471-2466/14/196mucus-filling the alveolar space. Because this mucus
abundantly contains pulmonary surfactant, SP-A binding
with phospholipids are considered to be profusely present
there. These findings are consistent with the preferential
leakage of SP-D into the bloodstream.
CD34 is known as a marker of vascular endothelium
[30,40]. Ebina et al. reported that relatively small vascular
endothelial cells, like capillaries, are more intensively
stained by CD34 antibodies than proximal vessels [41].
However, D2-40 is a marker of lymphatic endothelium
frequently used to detect the presence of lymphatic inva-




rom idiopathic pulmonary fibrosis (IPF) patients. (A-B) In normal tissue,
and (B) SP-D (brown). (C-D) In IPF lungs, the type II alveolar epithelial cells
n). (E-F) The thick mucus inside honeycomb cysts and ectatic respiratory
lood vessels (arrows) were often positive for (h) SP-D but not for (g) SP-A.
A B
Figure 5 Immunostaining of blood and lymphatic vessels in lung biopsies from idiopathic pulmonary fibrosis (IPF) patients. (A) The
capillary vessels were extremely developed, especially along the air space (red: CD34, brown: SP-A). (B) On the other hand, lymphatic vessels were
localized at the center of the stroma (red: D2-40, brown: SP-A).
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stroma, particularly near the alveolar space, in IPF lungs.
These capillaries were close to the regenerated type II
alveolar epithelial cells that where SP-A and SP-D positive.
Hisata et al. suggested that surfactant proteins may be
transferred from type II cells to endothelial cells of adjacent
capillaries in IPF lungs [42]. On the other hand, we showed
that lymphatic ducts are concentrated in the central portion
of fibrotic interstitium, away from the alveolar space and
type II cells. According to this positional relationship, sur-
factant proteins would leak into the bloodstream directly
via capillaries, and not through lymphatic ducts.
This study has some limitations. We should interpret
the concentrations in BALF not only from the viewpoint
of the leakage and clearance but also from that of the
alterations in the production amount in IPF lungs. Be-
cause both proteins have the important function to regu-
late the inflammatory cell response, their productions may
be altered in IPF lungs. Further examinations are required
regarding these issues. We used the data of BALF from
healthy volunteers who were investigated in our previous
study [26]. Because SP-A and SP-D levels in sera had not
been evaluated, it was not possible to obtain correlationsTable 4 Summary of SP-A and SP-D immunolocalization
in normal peripheral and IPF lungs
SP-A SP-D
Type II alveolar epithelial cells (in normal lungs) + +
Columnar ciliated cells − −
Regenerated type II alveolar epithelial cells ++ ++
Fibrous parenchyma − ~ + − ~ ±
Mucus in honeycomb cysts +++ − ~ ±
Inside small vessels − − ~ +
Elastic fibers in the wall of blood vessels + −
Immunostaining intensity: −, (none); ±, (more or less); +, (positive); ++,
(more intense); and +++, (very intense). SP-A, surfactant protein A; SP-D,
surfactant protein D; IPF, idiopathic pulmonary fibrosis.between BALF and serum levels in healthy subjects. In
addition, there was a disparity between demographic data
of these healthy subjects and those of IPF patients. Unfortu-
nately, because some original data from healthy subjects
had been lost, we could not include them in multivariate
analysis. We accordingly compared the data from IPF
patients with those from sarcoidosis patients as a disease
control. Demographic data from the patients, age, smoking
status, infection, and nutrition status might affect the per-
meability of alveolocapillary barrier. Although we found no
significant difference in smoking history or BALF recovery
between the IPF and SAR groups and any infection or
nutrition problems in these two groups, the age bias
remained. We confirmed a low BALF SP-D level in the IPF
group using multivariate analysis. Because the histopatho-
logical pattern of IPF shows temporal and spatial hetero-
geneity, the site of sampling may play an important role.
We collected BALF from the right middle lobe or lingula,
and obtained histologies from the most lesioned areas.
These contradictory sites may have affected the results of
our study. The new BAL guideline published by ATS in
2012 [43] recommends that the BAL target site should be
chosen on the basis of an high-resolution computed tom-
ography performed before the procedure in preference to a
“traditional BAL site” such as the right middle lobe or lin-
gula. Further studies should be conducted in accordance
with the new guideline. With reference to the immunohis-
tochemical study, we should mention the possibility that
SP-D might be more easily lost from the bronchoalveolar
space during immunohistochemistry process because of its
hydrophilicity. However we identified strong immunoreac-
tivity to SP-D in normal/hyperplastic type II alveolar epi-
thelial cells with the same degree to SP-A and believe that
this technical bias is small.
The histopathological features of IPF indicate a hetero-
geneous appearance. Honeycombing, in which type II
cells are replaced with regenerated ciliated epithelial
cells, is a finding that represents the end stage of fibrotic
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alveolitis is a potentially reversible and treatable paren-
chymal abnormality. In such a lesion, type II alveolar
epithelial cells are extremely hyperplastic. These variable
features may reflect dynamic differences between SP-A
and SP-D because of their hyprophilicity. If serum SP-D
levels mirror the severities of moderate and reversible
damage to the epithelium due to their ready leakage into
the bloodstream, these levels can be used as a biomarker
to predict therapeutic response. We need to assess the
utilities of these biomarkers with regard to the thera-
peutic effects of drugs such as antifibrotic agents.
Currently, KL-6, MMP-7 and CCL-18 have been also
reported as blood biomarkers of IPF [20-22]. Whereas
all of them are elevated in the serum of IPF patients,
they may accumulate for different reasons. Song et al.
suggested that multiple markers may be required to
improve the prediction of prognosis and disease progres-
sion in IPF patients [21]. We believe that simultaneous
measurements of several biomarkers with unique charac-
teristics will provide a more sensitive readout of the tem-
poral changes in pathological profile of IPF.
Conclusions
Although SP-A and SP-D are serum biomarkers of IPF
having high homology, the current study suggests that
the difference in hydrophilicity of the two proteins could
be the cause of their difference in migration from the air
space into the bloodstream. Because SP-D leaks into the
circulation more easily, serum levels of SP-D may reflect
pathological changes of the disease more sharply than
those of SP-A.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
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